Casma Therapeutics to Participate at 23rd Annual Needham Virtual Healthcare Conference and at UBS Virtual Targeted Protein Degradation Day

April 17, 2024

CAMBRIDGE, Mass., April 17, 2024 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy/lysosomal system to provide innovative new medicines, today announced that Frank Gentile, PhD, Chief Executive Officer, presented and participated in one-on-one meetings at the 23rd Annual Needham Virtual Healthcare Conference on April 5, 2024. Frank Gentile, PhD, will also attend and participate in one-on-one meetings at a virtual Targeted Protein Degradation Day, hosted by UBS on July 15, 2024.


About Casma Therapeutics

Casma Therapeutics is developing novel cellular degradation approaches based on the autophagy/lysosomal pathway to initiate new target areas for drug discovery and development that will profoundly impact the lives of patients. Autophagy is a conserved cellular process that contributes to overall cellular homeostasis. The autophagy machinery focuses on larger and more complex disease targets, such as organelles, protein aggregates, and large signaling complexes, and directs these targets to the lysosome for elimination. Through selective degradation of disease targets, Casma expects to arrest or reverse the progression of disease in multiple oncology, inflammation, neurodegeneration, and metabolic disorders.


Contact for Investors and Media

Courteney Backstrom
Casma Therapeutics, Inc.

Back to news & media

Keep reading: